6th ICHNO Abstract Book

page 16 6 th ICHNO Conference International Conference on innovative approaches in Head and Neck Oncology 16 – 18 March 2017 Barcelona, Spain __________________________________________________________________________________________ 6th ICHNO

average the GTV was 18.7cm 3 (range 6.4-66.7 cm 3 ). All patients had histological proven free bone tumor margins. Analysis of the accuracy of the cutting planes showed that the average deviation of the planned cutting plane was 2.1mm. Appr half of the cutting planes were closer placed to the tumor than planned with an average shift of 1.98 and 2.5 mm measured on the most cranial resp. caudal point of the buccal bone surface. Conclusions: This study reports a method for image fusion and 3D surgical planning using the hospitals existing software architecture. Tumor visualization by fusion of CT and MRI for integration of tumor margins seems a safe method in 3D virtual planning of surgical removal of oral squamous cell carcinoma. This approach allows us to visualize not only tumors but also other useful information for surgical planning such as radiotherapy isodose lines Abstract text Over recent decades the incidence of oropharynx cancer (OPSCC) has doubled in many countries of the Developed World. Whilst much of this increase has been attributed to infection with Human papillomavirus (HPV+), recent UK data confirm a parallel rise in HPV negative OPSCC. HPV+ OPSCC affects patients who are younger, fitter, drink less alcohol and smoke less than patients presenting with HPV- head and neck cancer. Whilst they typically present with clinico-pathological features (multiple cervical lymph nodes with a high prevalence of extracapsular spread) traditionally associated with aggressive behaviour and poor treatment outcome, they, paradoxically, respond better to treatment. Current treatments based on cisplatin based chemoradiotherapy (CRT), however, result in marked early and late toxicity, particularly with respect to swallowing function. Whilst most patients with HPV+ disease will experience a favourable survival outcome, a significant minority, together with patients presenting with HPV- disease, will do less well. This talk will highlight the contribution of contemporary surgery in the quest to develop novel 1. De-intensified treatment strategies for patients with favourable disease, in order to maintain current survival outcomes whilst reducing detrimental treatment-related effects on swallowing 2. More effective strategies for patients likely to experience a poorer outcome. SP-025 Oropharyngeal surgery T. Jones 1 1 University of Liverpool, Department of Molecular and Clinical Cancer Medicine, Liverpool, United Kingdom PD-026 Correlation and prognostic impact of HPV and p16 on RT-outcome in larynx and hypopharynx cancer P. Lassen 1 , M. Schou 1 , J. Overgaard 1 , J. Alsner 1 1 Aarhus University Hospital, Department of Experimental Clinical Oncology, Aarhus C, Denmark Purpose or Objective HPV has been found in head and neck cancer from all sites with a significantly higher prevalence in oropharyngeal carcinoma (OPC) compared to non-OPC. In previous randomised trials HPV-associated p16-expression has been shown to be the strongest independent factor for radiotherapy (RT) outcome in OPC. Outside OPC the correlation between HPV and p16 is less robust and the prognostic significance of p16/HPV less obvious. Previous analysis on DAHANCA patients found no prognostic impact of p16 outside OPC, but others have reported conflicting Poster discussion

findings. With this study we wanted to investigate the correlation between HPV and p16 in advanced larynx and hypopharynx cancer and furthermore to analyse the potential prognostic impact of both markers on overall survival after primary, curatively intended RT. Material and Methods One-hundred-nine patients with stage III-IV larynx and hypopharynx carcinoma were identified in the DAHANCA database. All patients were treated with curatively intended primary RT according to DAHANCA guidelines from 1986-2006. The patient cohort was enriched for p16- positive tumors and as such not representative for unselected patients. Pre-treatment tumour blocks were evaluated by immunohistochemistry for p16-expression and classified as positive in case of strong cytoplasmatic and nuclear staining in >70% of tumor cells and in consideration of the typical microscopic appearance of an HPV-related tumor. HPV DNA and RNA was analysed by qPCR using specific primer sets for HPV16 E6 and E7 and HPV18 E6 and E7. Internal reference genes were ERV3-1 and HBB for DNA and ACTR3 , NDFIP1 , and RPL37A for RNA. Results Twenty-six percent (19/74) of larynx cancers and 14% of hypopharynx cancers (5/35) were p16-positive. All p16- positive hypopharynx cancers were also positive for both HPV DNA and RNA. Of the 19 p16-positive larynx cancers only 1 was HPV DNA and RNA positive and 1 was HPV DNA positive but RNA negative. Only HPV subtype 16 was detected in case of HPV positivity. All p16-negative tumors were HPV-negative, regardless of tumor site. In univariate analysis overall survival was significantly associated with HPV/p16-status in hypophaynx: HR: 0.30 [95% CI: 0.09- 0.99], whereas in tumors of laryngeal origin no prognostic impact of p16–status was found: HR 0.85 [0.46-1.60]. See Figure 1. Conclusion Our findings indicate a strong correlation between HPV and p16-status in hypopharynx cancer where there also seem to be a significant impact of the markers on overall survival after primary RT comparable to what is seen in OPC. Although no firm conclusions can be drawn due to the limited sample size, we find that there is a need for more investigation in the subject in order to enable proper definition of the group of patients with HPV-associated tumors and favourable prognosis, both in OPC and hypopharynx. PD-027 cfHPV DNA as a marker of treatment results in patients with HPV-related head and neck cancer. T. Rutkowski 1 , A. Mazurek 2 , M. Snietura 3 , A. Wygoda 1 , M. Kentnowski 1 , P. Polanowski 1 , U. Dworzecka 1 , B. Pilecki 1 , K. Dębiec 1 , I. Gawron 1 , J. Niedziałek 1 , W. Pigłowski 3 , U. Bojko 2 , P. Widłak 2 , K. Składowski 1 1 Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Department of Radiation Oncology, Gliwice, Poland 2 Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Center for Translational Research and Molecular Biology of Cancer, Gliwice, Poland 3 Maria Sklodowska-Curie Memorial Cancer Center and